Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
Authors
Keywords
-
Journal
LEUKEMIA
Volume 24, Issue 6, Pages 1128-1138
Publisher
Springer Nature
Online
2010-04-29
DOI
10.1038/leu.2010.69
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma
- (2010) Fonnet E. Bleeker et al. ACTA NEUROPATHOLOGICA
- Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
- (2010) F. X. Schaub et al. BLOOD
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias
- (2010) O. Abdel-Wahab et al. CANCER RESEARCH
- The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations
- (2010) K. Paulsson et al. HUMAN MOLECULAR GENETICS
- Segregation of non-p.R132H mutations inIDH1in distinct molecular subtypes of glioma
- (2010) Lonneke A.M. Gravendeel et al. HUMAN MUTATION
- Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
- (2010) Stefan Gross et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms
- (2010) Anthony Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
- (2009) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- JAK redux: a second look at the regulation and role of JAKs in the heart
- (2009) Mazen Kurdi et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
- (2009) O. Abdel-Wahab et al. BLOOD
- In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm
- (2009) J. R. Lambert et al. BLOOD
- Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
- (2009) P. Guglielmelli et al. BLOOD
- Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor
- (2009) C. Pecquet et al. BLOOD
- Thrombosis in primary myelofibrosis: incidence and risk factors
- (2009) T. Barbui et al. BLOOD
- TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
- (2009) O. Kosmider et al. BLOOD
- Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia
- (2009) C. L. Fisher et al. BLOOD
- Ubiquitination and degradation of the thrombopoietin receptor c-Mpl
- (2009) S. J. Saur et al. BLOOD
- Mutations in CBL occur frequently in juvenile myelomonocytic leukemia
- (2009) M. L. Loh et al. BLOOD
- Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia
- (2009) H. Muramatsu et al. BLOOD
- E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease
- (2009) S. R. Bandi et al. BLOOD
- Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
- (2009) A. M. Jankowska et al. BLOOD
- Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
- (2009) F. H. Grand et al. BLOOD
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones
- (2009) Philip A. Beer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mutations of polycomb-associated geneASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia
- (2009) Véronique Gelsi-Boyer et al. BRITISH JOURNAL OF HAEMATOLOGY
- CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes
- (2009) C. Reindl et al. CLINICAL CANCER RESEARCH
- IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
- (2009) S. Nobusawa et al. CLINICAL CANCER RESEARCH
- Conventional cytogenetics in myelofibrosis: literature review and discussion
- (2009) Kebede Hussein et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia
- (2009) O. Kosmider et al. HAEMATOLOGICA
- Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis
- (2009) J. Flach et al. HAEMATOLOGICA
- Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis
- (2009) L. Teofili et al. HAEMATOLOGICA
- IDH1mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors
- (2009) Fonnet E. Bleeker et al. HUMAN MUTATION
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Absence of IDH2 codon 172 mutation in common human cancers
- (2009) Sang Wook Park et al. INTERNATIONAL JOURNAL OF CANCER
- Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
- (2009) Mi Ran Kang et al. INTERNATIONAL JOURNAL OF CANCER
- ASXL1 Represses Retinoic Acid Receptor-mediated Transcription through Associating with HP1 and LSD1
- (2009) Sang-Wang Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- STAT5 Activation Is Critical for the Transformation Mediated by Myeloproliferative Disorder-associated JAK2 V617F Mutant
- (2009) Megumi Funakoshi-Tago et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1
- (2009) Ayalew Tefferi JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Isocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas
- (2009) José Gaal et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies
- (2009) Hideki Makishima et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
- (2009) Michael Weller et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel TET2 Mutations Associated With UPD4q24 in Myelodysplastic Syndrome
- (2009) Azim M. Mohamedali et al. JOURNAL OF CLINICAL ONCOLOGY
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
- (2009) Marc Sanson et al. JOURNAL OF CLINICAL ONCOLOGY
- NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
- (2009) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- The complete evaluation of erythrocytosis: congenital and acquired
- (2009) M M Patnaik et al. LEUKEMIA
- No evidence of frequent association of the JAK2 V617F mutation with acute myocardial infarction in young patients
- (2009) M Politou et al. LEUKEMIA
- The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera
- (2009) D Olcaydu et al. LEUKEMIA
- MPLW515L mutation in acute megakaryoblastic leukaemia
- (2009) K Hussein et al. LEUKEMIA
- Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias
- (2009) L Couronné et al. LEUKEMIA
- The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status—clinical correlates in a study of 226 consecutive patients
- (2009) A Pardanani et al. LEUKEMIA
- JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
- (2009) A Tefferi et al. LEUKEMIA
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
- (2009) A Pardanani et al. LEUKEMIA
- Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias
- (2009) N Carbuccia et al. LEUKEMIA
- Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
- (2009) A Tefferi et al. LEUKEMIA
- Mutations of ASXL1 gene in myeloproliferative neoplasms
- (2009) N Carbuccia et al. LEUKEMIA
- TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
- (2009) A Tefferi et al. LEUKEMIA
- Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML
- (2009) A Tefferi et al. LEUKEMIA
- JAK2V617Fmutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients
- (2009) Francesca Palandri et al. LEUKEMIA & LYMPHOMA
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
- (2009) Mark A. Dawson et al. NATURE
- Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
- (2009) Masashi Sanada et al. NATURE
- A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
- (2009) Damla Olcaydu et al. NATURE GENETICS
- Acquired mutations in TET2 are common in myelodysplastic syndromes
- (2009) Saskia M C Langemeijer et al. NATURE GENETICS
- JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
- (2009) Amy V Jones et al. NATURE GENETICS
- Mutation inTET2in Myeloid Cancers
- (2009) NEW ENGLAND JOURNAL OF MEDICINE
- Myelodysplastic Syndromes
- (2009) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation inTET2in Myeloid Cancers
- (2009) François Delhommeau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
- (2009) Elaine R. Mardis et al. NEW ENGLAND JOURNAL OF MEDICINE
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- A progenitor cell origin of myeloid malignancies
- (2009) H. Haeno et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1
- (2009) S. Zhao et al. SCIENCE
- Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
- (2009) M. Tahiliani et al. SCIENCE
- Analysis of the IDH1 codon 132 mutation in brain tumors
- (2008) Jörg Balss et al. ACTA NEUROPATHOLOGICA
- The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity
- (2008) C. James et al. BLOOD
- Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F
- (2008) F. X. Schaub et al. BLOOD
- Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
- (2008) A. M. Vannucchi et al. BLOOD
- MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
- (2008) P. A. Beer et al. BLOOD
- Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
- (2008) O. Landgren et al. BLOOD
- JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
- (2008) I. Plo et al. BLOOD
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
- (2008) A. H. Schmitt-Graeff et al. HAEMATOLOGICA
- Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias
- (2008) S. Abbas et al. HAEMATOLOGICA
- Genetic complexity of myeloproliferative neoplasms
- (2008) R Kralovics LEUKEMIA
- UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation
- (2008) H Szpurka et al. LEUKEMIA
- New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition
- (2008) R Chaligné et al. LEUKEMIA
- Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation
- (2008) R Jamal et al. LEUKEMIA
- Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage
- (2008) B da Costa Reis Monte-Mór et al. LEUKEMIA
- Aberrant signal transduction pathways in myeloproliferative neoplasms
- (2008) J Kota et al. LEUKEMIA
- TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients
- (2008) T L Lasho et al. LEUKEMIA
- Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
- (2008) A Tefferi et al. LEUKEMIA
- Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
- (2008) A M Vannucchi et al. LEUKEMIA
- JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science
- (2008) O Kilpivaara et al. LEUKEMIA
- BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
- (2008) Charles G. Mullighan et al. NATURE
- Variable breakpoints target PAX5 in patients with dicentric chromosomes: A model for the basis of unbalanced translocations in cancer
- (2008) Q. An et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
- Canonical and non-canonical JAK–STAT signaling
- (2008) Willis X. Li TRENDS IN CELL BIOLOGY
- Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
- (2007) R. Tiedt et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now